Welcome to our dedicated page for MDFZF news (Ticker: MDFZF), a resource for investors and traders seeking the latest updates and insights on MDFZF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MDFZF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MDFZF's position in the market.
Medifocus, Inc. (OTC PINK:MDFZF) announced its decision to terminate its stock registration with the SEC and cease trading on OTC PINK. The Company plans to file for voluntary deregistration on May 20, 2022, and will suspend its reporting obligations under the Securities Exchange Act of 1934. This decision follows a review of ongoing balance sheet restructuring initiated in September 2021, with further updates promised as significant developments arise.
Medifocus, Inc. (OTC PINK:MDFZF) has initiated restructuring proceedings as of September 8, 2021, to seek creditor protection due to financial challenges exacerbated by the COVID-19 pandemic. The company's aim is to restructure its balance sheet while continuing normal operations. Medifocus has received a proposal for debtor-in-possession financing from its secured lender to facilitate the restructuring process. The company is optimistic about maintaining focus on developing effective treatments despite the proceedings.